All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Twelve months after a single shot of Valneva SE’s chikungunya vaccine, positive antibody persistence was found, threatening a deadly disease that has long resisted treatment. The new data are derived from a study of 363 healthy adult participants that followed them from month 6 after vaccination to month 12. Nearly all, 99%, kept their neutralizing antibody titers for 12 months beyond the seroresponse threshold of 150, which hit the primary endpoint and the antibody level agreed with regulators as endpoint under the accelerated approval pathway.
George Washington University has described N-ACYL fosmidomycin prodrug analogues acting as 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr; IspC) (Mycobacterium tuberculosis) and Dxr (Plasmodium falciparum) inhibitors reported to be useful for the treatment of malaria and tuberculosis.
A diverse group of government and academic researchers, marking World AIDS Day 2022, have published details of an investigational vaccine they said safely induced broadly neutralizing antibody-precursors against HIV in nearly all participants in a small phase I trial.
The U.S. FDA has approved its first fecal microbiota treatment. Rebyota (fecal microbiota, live-jslm), from privately held Ferring Pharmaceuticals Inc., is now approved to prevent recurring Clostridioides difficile infection (CDI) in adults. The Nov. 30 approval came about two months after the FDA’s Vaccines and Related Biological Products Advisory Committee voted 13-4 to support the microbiome therapy’s effectiveness in reducing recurrent CDI in adults after antibiotic treatment for recurrent CDI.
Quantbiores A/S has discovered peptides acting as spike glycoprotein (S) (SARS-CoV-2)/ACE2 interaction inhibitors reported to be useful for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19).
Texas A&M University System has discovered 3C-like proteinase (3CLpro) (SARS-CoV-2; COVID-19 virus) and cytochrome P450 3A4 (CYP3A4) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.
Biondvax Pharmaceuticals Ltd. has reported statistically significant efficacy results from an in vivo proof-of-concept study of its innovative inhaled nanosized antibody (NanoAb) COVID-19 therapy.
Animal models recapitulating the immune features of chronic hepatitis B (CHB) are very limited. An Osaka University research team has developed a novel murine model of CHB and tested the efficacy and immunomodulating effects of interferon-α (IFN-α) therapy.